Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients

Br J Dermatol. 2018 Sep;179(3):790-791. doi: 10.1111/bjd.16656. Epub 2018 Jun 25.

Authors

Y Mai¹, W Nishie¹, K Izumi¹, N Yoshimoto¹, Y Morita^{1

2}, M Watanabe¹, E Toyonaga¹, H Ujiie¹, H Iwata¹, Y Fujita¹, T Nomura¹, K C Sato-Matsumura³, S Shimizu⁴, H Shimizu¹

Affiliations

¹ Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan.
² Department of Dermatology, JR Sapporo Hospital, Sapporo, Japan.
³ Department of Dermatology, Japan Community Health Care Organization, Sapporo Hokushin Hospital, Sapporo, Japan.
⁴ Department of Dermatology, Sapporo City General Hospital, Sapporo, Japan.

PMID: 29624639
DOI: 10.1111/bjd.16656

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Aged, 80 and over
Autoantibodies / blood*
Autoantibodies / immunology
Autoantigens / immunology*
Collagen Type XVII
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
Female
Humans
Male
Non-Fibrillar Collagens / immunology*
Pemphigoid, Bullous / blood
Pemphigoid, Bullous / chemically induced*
Pemphigoid, Bullous / diagnosis
Pemphigoid, Bullous / immunology
Pyrazoles / adverse effects
Thiazolidines / adverse effects
Time Factors
Vildagliptin / adverse effects

Substances

3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
Autoantibodies
Autoantigens
Dipeptidyl-Peptidase IV Inhibitors
Non-Fibrillar Collagens
Pyrazoles
Thiazolidines
Vildagliptin